Search

Your search keyword '"Zeuzem S"' showing total 1,845 results
Start Over Author "Zeuzem S" Language english
1,845 results on '"Zeuzem S"'

1. Noninvasive screening identifies patients at risk for spontaneous bacterial peritonitis caused by multidrug-resistant organisms

Author

Ferstl PG, Müller M, Filmann N, Hogardt M, Kempf VAJ, Wichelhaus TA, Lange CM, Vermehren J, Zeuzem S, Reinheimer C, and Waidmann O

Subjects
Multidrug resistance, spontaneous bacterial peritonitis, screening routine, antibiotic therapy, Infectious and parasitic diseases, RC109-216
Abstract

Philip G Ferstl,1,2 Mona Müller,1 Natalie Filmann,3 Michael Hogardt,2,4,5 Volkhard AJ Kempf,2,4,5 Thomas A Wichelhaus,2,4,5 Christian M Lange,1,2 Johannes Vermehren,1,2 Stefan Zeuzem,1,2 Claudia Reinheimer,2,4,5 Oliver Waidmann1,2 1Department for Internal Medicine I/Gastroenterology and Hepatology, University Hospital Frankfurt, Frankfurt am Main, Germany; 2University Center for Infectious Diseases (UCI), University Hospital Frankfurt, Frankfurt am Main, Germany; 3Institute of Biostatistics and Mathematical Modeling, University Hospital Frankfurt, Frankfurt am Main, Germany; 4Institute of Medical Microbiology and Infection Control, University Hospital Frankfurt, Frankfurt am Main, Germany; 5University Center of Competence for Infection Control at the Universities Frankfurt, Giessen, and Marburg, Frankfurt am Main, State of Hesse, Germany Background and aims: Spontaneous bacterial peritonitis (SBP) is a severe complication of decompensated cirrhosis. The prevalence of multidrug-resistant organisms (MDROs) in patients with cirrhosis is increasing. Identification of patients at risk for SBP due to MDROs (ie, SBP with the evidence of MDROs or Stenotrophomonas maltophilia in ascitic culture, MDRO-SBP) is crucial to the early adaptation of antibiotic treatment in such patients. We therefore investigated whether MDROs found in ascitic cultures can also be found in specimens determined by noninvasive screening procedures.Patients and methods: This retrospective study was conducted at the liver center of the University Hospital Frankfurt, Germany. Between 2011 and 2016, patients with cirrhosis were included upon diagnosis of SBP and sample collection of aerobic/anaerobic ascitic cultures. Furthermore, the performance of at least one complete MDRO screening was mandatory for study inclusion.Results: Of 133 patients diagnosed with SBP, 75 (56.4%) had culture-positive SBP and 22 (16.5%) had MDRO-SBP. Multidrug-resistant Escherichia coli (10/22; 45.5%) and vancomycin-resistant enterococci (7/22; 36.4%) resembled the major causatives of MDRO-SBP. Rectal swabs identified MDROs in 17 of 22 patients (77.3%) who developed MDRO-SBP with a time-dependent sensitivity of 77% and 87% after 30 and 90 days upon testing, while negative predictive value was 83% and 76%, respectively. The majority of patients were included from intensive care unit or intermediate care unit.Conclusion: MDRO screening may serve as a noninvasive diagnostic tool to identify patients at risk for MDRO-SBP. Patients with decompensated cirrhosis should be screened for MDROs from the first day of inpatient treatment onward. Keywords: multidrug resistance, liver cirrhosis, ascites, screening routine, antibiotic therapy

Published
2018

3. Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories

Author

Razavi-Shearer, D., Child, H., Razavi-Shearer, K., Voeller, A., Razavi, H., Buti, M., Tacke, F., Terrault, N., Zeuzem, S., Abbas, Z., Aghemo, A., Akarca, U.S., Al Masri, N., Alalwan, A., Blomé, M. Alanko, Jerkeman, A., Aleman, S., Kamal, H., Alghamdi, A., Alghamdi, M., Alghamdi, S., Al-Hamoudi, W., Ali, E., Aljumah, A., Altraif, I., Amarsanaa, J., Asselah, T., Baatarkhuu, O., Babameto, A., Ben-Ari, Z., Berg, T., Biondi, M., Braga, W., Brandão-Mello, C., Brown, R., Brunetto, M., Cabezas, J., Cardoso, M., Martins, A., Chan, H.L.Y., Cheinquer, H., Chen, C.-J., Yang, H.-I., Chen, P.-J., Chien, C.-H., Chuang, W.-L., Garza, L. Cisneros, Coco, B., Coffin, C., Coppola, N., Cornberg, M., Craxi, A., Crespo, J., Cuko, L., De Ledinghen, V., Duberg, A.-S., Etzion, O., Ferraz, M.L., Ferreira, P., Forns, X., Foster, G., Fung, J., Gaeta, G., García-Samaniego, J., Genov, J., Gheorghe, L., Gholam, P., Gish, R., Glenn, J., Hamid, S., Hercun, J., Hsu, Y.-C., Hu, C.-C., Huang, J.-F., Idilman, R., Jafri, W., Janjua, N., Jelev, D., Jia, J., Kåberg, M., Kaita, K., Kao, J.-H., Khan, A., Kim, D.Y., Kondili, L., Lagging, M., Lampertico, P., Lázaro, P., Lazarus, J.V., Lee, M.-H., Lim, Y.-S., Lobato, C., Macedo, G., Marinho, R., Marotta, P., Mendes-Correa, M.C., Méndez-Sánchez, N., Navas, M.-C., Ning, Q., Örmeci, N., Orrego, M., Osiowy, C., Pan, C., Pessoa, M., Piracha, Z., Pop, C., Qureshi, H., Raimondo, G., Ramji, A., Ribeiro, S., Ríos-Hincapié, C., Rodríguez, M., Rosenberg, W., Roulot, D., Ryder, S., Saeed, U., Safadi, R., Shouval, D., Sanai, F., Sanchez-Avila, J.F., Santantonio, T., Sarrazin, C., Seto, W.-K., Simonova, M., Tanaka, J., Tergast, T., Tsendsuren, O., Valente, C., Villalobos-Salcedo, J.M., Waheed, Y., Wong, G., Wong, V., Yip, T., Wu, J.-C., Yu, M.-L., Yuen, M.-F., Yurdaydin, C., and Zuckerman, E.

Published
2024
Full Text
View/download PDF

6. Recycling potential of gastrointestinal endoscopy in German hospitals and offices – a multicentre prospective study.

Author

Welsch, L., Kim, S., Tal, A., Haider, N., Eickhoff, A., Schneider, M., Wittersheim, L., Schmitt, L., Heilani, M., Zeuzem, S., Friedrich-Rust, M., and Michael, F.

Subjects
MEDICAL offices, OFFICES, MULTIHOSPITAL systems, ENDOSCOPY, LONGITUDINAL method, HOSPITALS
Abstract

This article presents the findings of a study on the amount of waste generated during gastrointestinal endoscopic examinations in German hospitals and offices. The study aimed to calculate the recycling potential of this waste. Over a four-week period, waste was collected and categorized into residual waste, accessories, personal protective equipment, plastics, and paper. The study found that an average of 1.15 kg of waste was generated per examination, with 69.9% being residual waste. Although the recycling potential for plastic and paper was low, it could still contribute to reducing the amount of residual waste. [Extracted from the article]

Published
2024
Full Text
View/download PDF

13. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II)

Author

Zeuzem, S., Flisiak, R., Vierling, J. M., Mazur, W., Mazzella, G., Thongsawat, S., Abdurakhmanov, D., Van Kính, N., Calistru, P., Heo, J., Stanciu, C., Gould, M., Makara, M., Hsu, S.-J., Buggisch, P., Samuel, D., Mutimer, D., Nault, B., Merz, M., Bao, W., Griffel, L. H., Brass, C., Naoumov, N. V., Tanno, Hugo, Bessone, Fernando, Terg, Ruben, Frider, Bernardo, Bertuzzi, Romina, Desmond, Paul, Zekry, Amany, Weltman, Martin, George, Jacob, Crawford, Darrell, Matthews, Gail, Moreno, Christophe, Van Vlierberghe, Hans, Reynaert, Hendrik, Gould, Michael, Lee, Samuel, Ramji, Alnoor, Tam, Edward, Marotta, Paul, Yoshida, Eric, Wong, Florence, Feld, Jordan, Samuel, Didier, Marcellin, Patrick, Alric, Laurent, Zarski, Jean-Pierre, Zoulim, Fabien, Buggisch, Peter, Hinrichsen, Holger, Goeser, Tobias, Zeuzem, Stefan, Galle, Peter, Berg, Thomas, Schott, Eckart, Rasenack, Jens, Gerken, Guido, Wedemeyer, Hans, Tsang, Owen, Yuen, Man-Fung, Chan, Henry, Hui, Aric Josun, Makara, Mihaly, Tornai, Istvan, Gervain, Judit, Szalay, Ferenc, Varga, Marta, Horvath, Gabor, Hunyady, Bela, Vincze, Aron, Mazzella, Giuseppe, Gaeta, Giovanni Battista, Alberti, Alfredo, Colombo, Massimo, Andreone, Pietro, Rizzetto, Mario, Angelico, Mario, Craxi, Antonio, Picciotto, Antonino, Sacchi, Paolo, Vinci, Maria, Invernizzi, Pietro, Bruno, Savino, Heo, Jeong, Lee, Younjae, Cho, Mong, Han, Sangyoung, Lee, Jinwoo, Ahn, Sanghoon, Lim, Youngsuk, Hwang, Seonggyu, Sanchez, Juan, Muñoz, Linda, Maldonado, Hector, Mazur, Wlodzimierz, Flisiak, Robert, Jablkowski, Maciej, Kryczka, Wieslaw, Halota, Waldemar, Calistru, Petre, Prelipcean, Cristina, Musa, Manuela, Stanciu, Carol, Manuc, Mircea, Tanasescu, Coman, Dumitrascu, Dan, Abdurakhmanov, Djamal, Chulanov, Vladimir, Nikitin, Igor, Zhdanov, Konstantin, Esaulenko, Elena, Maevskaya, Marina, Znoyko, Olga, Lamoglia, Ricard Sola, Ferret, Maria Buti, Garcia-Samaniego, Javier, Gomez, Manuel Romero, Diago, Moises, Calleja, Jose Luis, Hsu, Shih-Jer, Chuang, Wan-Long, Hu, Tsung-Hui, Peng, Cheng-Yuan, Chen, Chi-Yi, Kao, Jia-Horng, Thongsawat, Satawat, Sukeepaisarnjaroen, Wattana, Piratvisuth, Teerha, Tanwandee, Tawesak, Komolmit, Piyawat, Agarwal, Kosh, Mutimer, David, Brown, Ashley, Foster, Graham, McPherson, Stuart, Ryder, Stephen, Poulos, John, Rustgi, Vinod, Lyche, Kip, Omarro, Steven, Vierling, John, Ghalib, Reem, Karnam, Umaprasanna, Peine, Craig, Galati, Joseph, Person, John, De La Torre, Andrew, Ravendhran, Natarajan, Mushahwar, Andria, OʼLeary, Jacqueline, Lee, William, Lawitz, Eric, Ankoma-Sey, Victor, King, John, Pound, David, Scarsella, Anthony, Thuluvath, Paul, Pockros, Paul, Mailliard, Mark, Shiffman, Mitchell, Sylvestre, Diana, Heiman, David, Jacobson, Ira, Bacon, Bruce, Dimitroff, James, Reindollar, Robert, Tobias, Hillel, Godofsky, Eliot, Rodriguez-Torres, Maribel, Bennett, Michael, Ben-Zvi, Jeffrey, Van, Kinh Nguyen, Dao, Long, Huu, Hoang Bui, Minh, Yen Lam, Le Thanh, Ly, and Van Long, Dao

Published
2015
Full Text
View/download PDF

25. A transient early HBV-DNA increase during PEG-IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction

Author

Anastasiou, O.E. Yurdaydin, C. Maasoumy, B. Hardtke, S. Caruntu, F.A. Curescu, M.G. Yalcin, K. Akarca, U.S. Gürel, S. Zeuzem, S. Erhardt, A. Lüth, S. Papatheodoridis, G.V. Radu, M. Liebig, S. Bantel, H. Bremer, B. Manns, M.P. Cornberg, M. Wedemeyer, H.

Subjects
virus diseases, digestive system diseases
Abstract

HBV-DNA levels are low or even undetectable in the majority HDV-infected patients. The impact of PEG-IFNα on HBV-DNA kinetics in HDV-infected patients has not been studied in detail. We analysed data of a prospective treatment trial where 120 HDV-RNA–positive patients were randomized to receive PEG-IFNα-2a plus tenofovir-disoproxil-fumarate (PEG-IFNα/TDF, n = 59) or placebo (PEG-IFNα/PBO; n = 61) for 96 weeks. At week 96, HBV-DNA was still quantifiable in 71% of PEG-IFNα/PBO-treated patients but also in 76% of PEG-IFNα/TDF-treated patients, despite low HBV-DNA baseline values. Surprisingly, a transient HBV-DNA increase between weeks 12 and 36 was observed in 12 in PEG-IFNα/TDF-treated and 12 PEG-IFNα/PBO-treated patients. This increase was positively associated with HBsAg loss [(P = 0.049, odds ratio (OR) 5.1] and HDV-RNA suppression (P = 0.007, OR 4.1) at week 96. Biochemical markers of cell death (M30 and ALT) were higher during the HBV-DNA peak but no distinct systemic immune pattern could be observed by screening 91 soluble inflammatory markers. In conclusion, an early increase in HBV-DNA during PEG-IFNα-2a therapy occurred in more than 20% of patients, even in TDF-treated patients. This transient HBV-DNA rise may indicate PEG-IFNα–induced cell death and lead to long-term HDV-RNA suppression and HBsAg loss. © 2020 John Wiley & Sons Ltd

Published
2021

26. Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study

Author

Bremer, B. Anastasiou, O.E. Hardtke, S. Caruntu, F.A. Curescu, M.G. Yalcin, K. Akarca, U.S. Gürel, S. Zeuzem, S. Erhardt, A. Lüth, S. Papatheodoridis, G.V. Radu, M. Idilman, R. Manns, M.P. Cornberg, M. Yurdaydin, C. Wedemeyer, H.

Subjects
viruses, virus diseases, biochemical phenomena, metabolism, and nutrition
Abstract

The role of low levels of HDV-RNA during and after interferon therapy of hepatitis D is unknown. We re-analysed HDV RNA in 372 samples collected in the HIDIT-2 trial (Wedemeyer et al, Lancet Infectious Diseases 2019) with the Robogene assay (RA; Jena Analytics). Data were compared with the previously reported in-house assay (IA). We detected HDV-RNA in one-third of samples previously classified as undetectable using the highly sensitive RA. Low HDV viraemia detectable at week 48 or week 96 was associated with a high risk for post-treatment relapse, defined as HDV RNA positivity in both assays at week 120. HDV RNA relapses occurred in 10/15 (67%) patients with detectable low HDV RNA at week 48 and in 10/13 (77%) patients with low viraemia samples at week 96. In contrast, the post-treatment relapse rate was lower in patients with undetectable HDV RNA in both assays during treatment. © 2020 The Authors. Liver International published by John Wiley & Sons Ltd

Published
2021

27. The case for simplifying and using absolute targets for viral hepatitis elimination goals

Author

Razavi, H. Blach, S. Razavi-Shearer, D. Abaalkhail, F. Abbas, Z. Abdallah, A. Abrao Ferreira, P. Abu Raddad, L.J. Adda, D. Agarwal, K. Aghemo, A. Ahmed, A. Al-Busafi, S.A. Al-hamoudi, W. Al-Kaabi, S. Al-Romaihi, H. Aljarallah, B. AlNaamani, K. Alqahtani, S. Alswat, K. Altraif, I. Asselah, T. Bacon, B. Bessone, F. Bizri, A.R. Block, T. Bonino, F. Brandão-Mello, C.E. Brown, K. Bruggmann, P. Brunetto, M.R. Buti, M. Cabezas, J. Calleja, J.L. Castro Batänjer, E. Chan, H.L.-Y. Chang, H. Chen, C.-J. Christensen, P.B. Chuang, W.-L. Cisneros, L. Cohen, C. Colombo, M. Conway, B. Cooper, C. Craxi, A. Crespo, J. Croes, E. Cryer, D. Cupertino de Barros, F.P. Derbala, M. Dillon, J. Doss, W. Dou, X. Doyle, J. Duberg, A.-S. Dugan, E. Dunn, R. Dusheiko, G. El Khayat, H. El-Sayed, M.H. Eshraghian, A. Esmat, G. Esteban Mur, R. Ezzat, S. Falconer, K. Fassio, E. Ferrinho, P. Flamm, S. Flisiak, R. Foster, G. Fung, J. García-Samaniego, J. Gish, R.G. Gonçales, F. Halota, W. Hamoudi, W. Hassany, M. Hatzakis, A. Hay, S. Himatt, S. Hoepelman, I.M. Hsu, Y.-C. Hui, Y.T. Hunyady, B. Jacobson, I. Janjua, N. Janssen, H. Jarcuska, P. Kabagambe, K. Kanto, T. Kao, J.-H. Kaymakoglu, S. Kershenobich, D. Khamis, F. Kim, D.J. Kim, D.Y. Kondili, L.A. Kottilil, S. Kramvis, A. Kugelmas, M. Kurosaki, M. Lacombe, K. Lagging, M. Lao, W.-C. Lavanchy, D. Lazarus, J.V. Lee, A. Lee, S.S. Levy, M. Liakina, V. Lim, Y.-S. Liu, S. Maddrey, W. Malekzadeh, R. Marinho, R.T. Mathur, P. Maticic, M. Mendes Correa, M.C. Mera, J. Merat, S. Mogawer, S. Mohamed, R. Muellhaupt, B. Muljono, D. Mostafa, I. Nahum, M.S. Nawaz, A. Negro, F. Ninburg, M. Ning, Q. Ntiri- Reid, B. Nymadawa, P. Oevrehus, A. Ormeci, N. Orrego, M. Osman, A. Oyunsuren, T. Pan, C. Papaevangelou, V. Papatheodoridis, G. Popping, S. Prasad, P. Prithiviputh, R. Qureshi, H. Ramji, A. Razavi-Shearer, K. Reddy, R. Remak, W. Richter, C. Ridruejo, E. Robaeys, G. Roberts, S. Roberts, L. Roudot-Thoraval, F. Saab, S. Said, S. Salamat, A. Sanai, F. Sanchez-Avila, J.F. Schiff, E. Schinazi, R. Sebastiani, G. Seguin-Devaux, C. Shanmugam, R.P. Sharara, A. Shilton, S. Shouval, D. Sievert, W. Simonova, M. Sohrabpour, A.A. Sonderup, M. Soza, A. Wendy Spearman, C. Steinfurth, N. Sulkowski, M. Tan, S.-S. Tanaka, J. Tashi, D. Thein, H.-H. Thompson, P. Tolmane, I. Toy, M. Valantinas, J. Van de Vijver, D. Vélez-Möller, P. Vince, A. Waked, I. Wang, S. Wedemeyer, H. Wong, V. Xie, Q. Yamada, S. Yang, H.-I. Yesmembetov, K. Yilmaz, Y. Younossi, Z. Yu, M.-L. Yuen, M.-F. Yurdaydin, C. Yusuf, A. Zekry, A. Zeuzem, S. Polaris Observatory Collaborators

Subjects
digestive system diseases
Abstract

The 69th World Health Assembly endorsed the Global Health Sector Strategy for Viral Hepatitis, embracing a goal to eliminate hepatitis infection as a public health threat by 2030. This was followed by the World Health Organization's (WHO) global targets for the care and management of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. These announcements and targets were important in raising awareness and calling for action; however, tracking countries’ progress towards these elimination goals has provided insights to the limitations of these targets. The existing targets compare a country's progress relative to its 2015 values, penalizing countries who started their programmes prior to 2015, countries with a young population, or countries with a low prevalence. We recommend that (1) WHO simplify the hepatitis elimination targets, (2) change to absolute targets and (3) allow countries to achieve these disease targets with their own service coverage initiatives that will have the maximum impact. The recommended targets are as follows: reduce HCV new chronic cases to ≤5 per 100 000, reduce HBV prevalence among 1-year-olds to ≤0.1%, reduce HBV and HCV mortality to ≤5 per 100 000, and demonstrate HBV and HCV year-to-year decrease in new HCV- and HBV-related HCC cases. The objective of our recommendations is not to lower expectations or diminish the hepatitis elimination standards, but to provide clearer targets that recognize the past and current elimination efforts by countries, help measure progress towards true elimination, and motivate other countries to follow suit. © 2020 John Wiley & Sons Ltd

Published
2021

28. Daclatasvir vs telaprevir in combination with peginterferon alfa/ribavirin in treatment-naive patients with HCV genotype 1: phase 3 COMMAND-3 results: O213

Author

Jacobson, I, Zeuzem, S, Flisiak, R, Knysz, B, Lueth, S, Zarebska-Michaluk, D, Janczewska, E, Ferenci, P, Diago, M, Zignego, A, Safadi, R, Baruch, Y, Abdurakhmanov, D, Shafran, S, Thabut, D, Bruck, R, Gadano, A, Thompson, A, Kopit, J, McPhee, F, Michener, T, Hughes, E, Yin, P, and Noviello, S

Published
2014
Full Text
View/download PDF

45. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

Author

Sands BE1, Peyrin-Biroulet L1, Loftus EV Jr1, Danese S1, Colombel JF1, Törüner M1, Jonaitis L1, Abhyankar B1, Chen J1, Rogers R1, Lirio RA1, Bornstein JD1, Schreiber S1, Calvo S, Gimenez E, Resk JH, Tron EP, Al-Ansari M, Andrews J, Bampton P, Debinski H, Hendy P, Holtmann G, Leong R, Moore G, Hindryckx P, Barac T, Draganova R, Kotzev I, Marinova I, Markov M, Mihaylov Y, Pavlov D, Penkova M, Petrov A, Spassova Z, Stoyanova D, Velev E, Vladimirov B, Yanev F, Axler J, Fedorak R, Fowler S Jr, Halder S, Jairath V, Ponich T, Wong K, Baez E, Ricardo J, Velasquez M, Banic M, Bogadi I, Borzan V, Zgrablic JC, Duvnjak M, Gusej M, Krznaric Z, Cechova I, Hala T, Janu L, Kohout P, Lukas M, Machkova M, Matous J, Ulbrych J, Vanasek T, Klinge L, Rannem T, Theede K, Borissova J, Kull K, Amil M, Bouhnik Y, Gilleta C, Fumery M, Grimaud JC, Hebuterne X, Laharie D, Moreau J, Peyrin-Biroulet L, Roblin X, Baumgart D, Buening C, Dinter J, Gauss A, Kuehbacher T, Fareed Rahman K, Schiefke I, Schreiber S, Von Amim U, Zeuzem S, Leung WK, Kin Kong Li M, Altorjay I, Bene L, Lakatos P, Molnar T, Salamon A, Schnabel R, Tulassay Z, Avni Y, Barkay O, Fishman S, Goldin E, Keret D, Lahat-Zok A, Melzer E, Naftali T, Nimer A, Ovadia B, Zittan E, Andriulli A, Cappello M, Castiglione F, Danese S, Fries W, Gionchetti P, Kohn A, Maconi G, Santino M, Savarino E, Privitera A, Romano M, Vecchi M, Villa E, Cheon JH, Han DS, Jang BI, Jeen YT, Kim JS, Kim SK, Kim HJ, Kim Y, Lee KM, Lee BI, Park DI, Park YS, Song GA, Ye BD, Pokrotnieks J, Tolmanis I, Denapiene G, Kancauskas A, Jakovlevaite V, Jonaitis L, Cruz Palacios A, Larriva de Los Reyes E, Asela Lujano Nicolas L, Mendoza Fuerte E, D'Haens G, Pierik M, Van Der Woude J, Adrych K, Danilkiewicz WC, Gawdis-Wojnarska B, Hartleb M, Karczewski M, Kierkus J, Malecka-Panas E, Petryka R, Piotrowski W, Regula J, Romatowski J, Rozciecha J, Rydzewska G, Smolinski P, Walczak P, Walczak M, Wozniak-Stolarska B, Cotter J, Lopes L, Portela F, Rodrigues Carvalho J, Simona Gheorghe L, Goldis AE, Mateescu RB, Abdulkhakov R, Agafyina A, Alexeeva O, Alikhanov B, Bunkova E, Dvorkin M, Gubonina I, Kashnikov V, Livzan M, Osipenko M, Parfenov A, Pershko A, Pesegova M, Rafalskiy V, Reshetko O, Simanenkov V, Tsybulko S, Valuyskikh E, Yakovlev A, Cvetkovic M, Damjanov D, Djuranovic S, Dugalic P, Nagorni A, Svorcan P, Zdravkovic Petrovic N, Bunganic I, Gregus M, Hlavaty T, Horvath F, Domenech Morral E, Jover Martinez R, Mendoza MIV, Shieh MJ, Wei CC, Altintas E, Atug O, Gonen C, Hamzaoglu H, Hulagu S, Toruner M, Chopey I, Danyliuk S, Datsenko O, Golovchenko N, Golovchenko O, Hospodarskyy I, Ivanov V, Klymenko V, Levchenko O, Lizogub V, Mostovoy Y, Oliinyk O, Polianskyi I, Pyrohovskyi V, Shevchuk S, Ursol G, Vdovychenko V, Vyshyvanyuk V, Beales I, Brookes M, Nwokolo C, Winter J, Aggarwal A, Aguilar H, Alnoah Z, Arce-Nunez E, Arimie C, Arterburn J, Baum C, Bellaguarda E, Bock B, Boone T, Callahan N, Chapman J, Chen S, Chiorean M, Coates A, Connor M, Dellon S, Dryden G, Du Vall G, Flores L, Fogel R, Frias J, Ginsburg P, Greenberg E, Grunkemeier D, Hellstern P, Herfarth H, Hoffman B, Horst S, Idarraga S, Iskandar H, Jain R, Jenkins E, Kaufman B, Khaleq A, Khan A, Khurana S, Lake J, Leavitt J, Leman B, Lewis D, Lindenberg D, Loftus EV, Korman L, Martin J, McCullough M, McNair A, Mehta N, Mutlu E, Narayen V, Paoli-Bruno J, Perez N, Phillips R, Raijman I, Ramirez-Vega R, Randall C, Rinesmith S, Ritter T, Safdi A, Saltzman M, Sands B, Seminerio J, Schulman M, Sedghi S, Shafran I, Shankar M, Silvers D, Soloman N, Tatum H, Tepper R, Tiongco F, Valdes M, Weber J, Zhang C., Sands, Be1, Peyrin-Biroulet, L1, Loftus EV, Jr1, Danese, S1, Colombel, Jf1, Törüner, M1, Jonaitis, L1, Abhyankar, B1, Chen, J1, Rogers, R1, Lirio, Ra1, Bornstein, Jd1, Schreiber, S1, Calvo, S, Gimenez, E, Resk, Jh, Tron, Ep, Al-Ansari, M, Andrews, J, Bampton, P, Debinski, H, Hendy, P, Holtmann, G, Leong, R, Moore, G, Hindryckx, P, Barac, T, Draganova, R, Kotzev, I, Marinova, I, Markov, M, Mihaylov, Y, Pavlov, D, Penkova, M, Petrov, A, Spassova, Z, Stoyanova, D, Velev, E, Vladimirov, B, Yanev, F, Axler, J, Fedorak, R, Fowler, S Jr, Halder, S, Jairath, V, Ponich, T, Wong, K, Baez, E, Ricardo, J, Velasquez, M, Banic, M, Bogadi, I, Borzan, V, Zgrablic, Jc, Duvnjak, M, Gusej, M, Krznaric, Z, Cechova, I, Hala, T, Janu, L, Kohout, P, Lukas, M, Machkova, M, Matous, J, Ulbrych, J, Vanasek, T, Klinge, L, Rannem, T, Theede, K, Borissova, J, Kull, K, Amil, M, Bouhnik, Y, Gilleta, C, Fumery, M, Grimaud, Jc, Hebuterne, X, Laharie, D, Moreau, J, Peyrin-Biroulet, L, Roblin, X, Baumgart, D, Buening, C, Dinter, J, Gauss, A, Kuehbacher, T, Fareed Rahman, K, Schiefke, I, Schreiber, S, Von Amim, U, Zeuzem, S, Leung, Wk, Kin Kong Li, M, Altorjay, I, Bene, L, Lakatos, P, Molnar, T, Salamon, A, Schnabel, R, Tulassay, Z, Avni, Y, Barkay, O, Fishman, S, Goldin, E, Keret, D, Lahat-Zok, A, Melzer, E, Naftali, T, Nimer, A, Ovadia, B, Zittan, E, Andriulli, A, Cappello, M, Castiglione, F, Danese, S, Fries, W, Gionchetti, P, Kohn, A, Maconi, G, Santino, M, Savarino, E, Privitera, A, Romano, M, Vecchi, M, Villa, E, Cheon, Jh, Han, D, Jang, Bi, Jeen, Yt, Kim, J, Kim, Sk, Kim, Hj, Kim, Y, Lee, Km, Lee, Bi, Park, Di, Park, Y, Song, Ga, Ye, Bd, Pokrotnieks, J, Tolmanis, I, Denapiene, G, Kancauskas, A, Jakovlevaite, V, Jonaitis, L, Cruz Palacios, A, Larriva de Los Reyes, E, Asela Lujano Nicolas, L, Mendoza Fuerte, E, D'Haens, G, Pierik, M, Van Der Woude, J, Adrych, K, Danilkiewicz, Wc, Gawdis-Wojnarska, B, Hartleb, M, Karczewski, M, Kierkus, J, Malecka-Panas, E, Petryka, R, Piotrowski, W, Regula, J, Romatowski, J, Rozciecha, J, Rydzewska, G, Smolinski, P, Walczak, P, Walczak, M, Wozniak-Stolarska, B, Cotter, J, Lopes, L, Portela, F, Rodrigues Carvalho, J, Simona Gheorghe, L, Goldis, Ae, Mateescu, Rb, Abdulkhakov, R, Agafyina, A, Alexeeva, O, Alikhanov, B, Bunkova, E, Dvorkin, M, Gubonina, I, Kashnikov, V, Livzan, M, Osipenko, M, Parfenov, A, Pershko, A, Pesegova, M, Rafalskiy, V, Reshetko, O, Simanenkov, V, Tsybulko, S, Valuyskikh, E, Yakovlev, A, Cvetkovic, M, Damjanov, D, Djuranovic, S, Dugalic, P, Nagorni, A, Svorcan, P, Zdravkovic Petrovic, N, Bunganic, I, Gregus, M, Hlavaty, T, Horvath, F, Domenech Morral, E, Jover Martinez, R, Mendoza, Miv, Shieh, Mj, Wei, Cc, Altintas, E, Atug, O, Gonen, C, Hamzaoglu, H, Hulagu, S, Toruner, M, Chopey, I, Danyliuk, S, Datsenko, O, Golovchenko, N, Golovchenko, O, Hospodarskyy, I, Ivanov, V, Klymenko, V, Levchenko, O, Lizogub, V, Mostovoy, Y, Oliinyk, O, Polianskyi, I, Pyrohovskyi, V, Shevchuk, S, Ursol, G, Vdovychenko, V, Vyshyvanyuk, V, Beales, I, Brookes, M, Nwokolo, C, Winter, J, Aggarwal, A, Aguilar, H, Alnoah, Z, Arce-Nunez, E, Arimie, C, Arterburn, J, Baum, C, Bellaguarda, E, Bock, B, Boone, T, Callahan, N, Chapman, J, Chen, S, Chiorean, M, Coates, A, Connor, M, Dellon, S, Dryden, G, Du Vall, G, Flores, L, Fogel, R, Frias, J, Ginsburg, P, Greenberg, E, Grunkemeier, D, Hellstern, P, Herfarth, H, Hoffman, B, Horst, S, Idarraga, S, Iskandar, H, Jain, R, Jenkins, E, Kaufman, B, Khaleq, A, Khan, A, Khurana, S, Lake, J, Leavitt, J, Leman, B, Lewis, D, Lindenberg, D, Loftus, Ev, Korman, L, Martin, J, Mccullough, M, Mcnair, A, Mehta, N, Mutlu, E, Narayen, V, Paoli-Bruno, J, Perez, N, Phillips, R, Raijman, I, Ramirez-Vega, R, Randall, C, Rinesmith, S, Ritter, T, Safdi, A, Saltzman, M, Sands, B, Seminerio, J, Schulman, M, Sedghi, S, Shafran, I, Shankar, M, Silvers, D, Soloman, N, Tatum, H, Tepper, R, Tiongco, F, Valdes, M, Weber, J, and Zhang, C.

Published
2019

50. Faldaprevir plus pegylated interferon alfa-2A and ribavirin in chronic HCV genotype-1 treatment-naïve patients: Final results from startverso1, a randomised, double-blind, placebo-controlled phase III trial

Author

FERENCI, P, ASSELAH, T, FOSTER, G R, ZEUZEM, S, SARRAZIN, C, MORENO, C, OUZAN, D, MAEVSKAYA, M, CALINAS, F, MORANO, L E, CRESPO, J, DUFOUR, J-F, BOURLIERE, M, AGARWAL, K, FORTON, D, SCHUCHMANN, M, ZEHNTER, E, NISHIGUCHI, S, OMATA, M, STERN, J, DATZENKO, Y, SCHERER, J, and QUINSON, A M

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results